KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $55.7 million.

  • Vertex Pharmaceuticals' Depreciation & Amortization (CF) rose 1978.49% to $55.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $209.8 million, marking a year-over-year increase of 125.48%. This contributed to the annual value of $209.8 million for FY2025, which is 125.48% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Depreciation & Amortization (CF) is $55.7 million, which was up 1978.49% from $54.0 million recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $59.0 million during Q4 2023, and its lowest value of $28.8 million during Q1 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $41.8 million in 2023 and averaged $43.6 million.
  • In the last 5 years, Vertex Pharmaceuticals' Depreciation & Amortization (CF) skyrocketed by 5364.58% in 2023 and then plummeted by 2118.64% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Depreciation & Amortization (CF) stood at $33.8 million in 2021, then grew by 13.61% to $38.4 million in 2022, then soared by 53.65% to $59.0 million in 2023, then decreased by 21.19% to $46.5 million in 2024, then increased by 19.78% to $55.7 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $55.7 million for Q4 2025, versus $54.0 million for Q3 2025 and $51.7 million for Q2 2025.